Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Subscribe To Our Newsletter & Stay Updated